Home » Stocks » Krystal Biotech

Krystal Biotech, Inc. (KRYS)

Stock Price: $40.12 USD -1.06 (-2.57%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 788.92M
Revenue (ttm) n/a
Net Income (ttm) -20.32M
Shares Out 17.39M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $40.12
Previous Close $41.18
Change ($) -1.06
Change (%) -2.57%
Day's Open 41.00
Day's Range 40.00 - 42.56
Day's Volume 165,472
52-Week Range 31.89 - 66.85

More Stats

Market Cap 788.92M
Enterprise Value 605.43M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.39M
Float 13.54M
EPS (basic) -1.24
EPS (diluted) -1.24
FCF / Share -1.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.58M
Short Ratio 7.74
Short % of Float 10.61%
Beta 1.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.96
Revenue n/a
Operating Income -23.33M
Net Income -20.32M
Free Cash Flow -27.93M
Net Cash 183.49M
Net Cash / Share 9.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -5.83%
ROE -8.58%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(95.04% upside)
Current: $40.12
Target: 78.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-22.08-11.92-4.77-1.14
Net Income-19.09-10.89-7.92-1.15
Shares Outstanding15.9011.205.360.88
Earnings Per Share-1.20-0.97-1.48-1.31
Operating Cash Flow-18.71-9.45-3.89-1.31
Capital Expenditures-6.40-2.23-0.21-0.02
Free Cash Flow-25.11-11.68-4.10-1.33
Cash & Equivalents19411249.591.92
Total Debt3.26--1.84
Net Cash / Debt19011249.590.08
Book Value20311349.470.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Krystal Biotech, Inc.
Country United States
Employees 51
CEO Krish S. Krishnan

Stock Information

Ticker Symbol KRYS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KRYS
IPO Date September 20, 2017


Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.